Rising Research and Development is driving the Lupus Therapeutic Market Growth

 

Lupus Therapeutic Market

Lupus Therapeutic Market, By Type (Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus, Drug-Induced Lupus Erythematosus, Neonatal Lupus), Treatment (Corticosteroids, Immunosuppressive Drugs, Biologic Drugs, Antihypertensive Drugs, Others), Diagnosis (Laboratory Tests, Biopsy, Imaging Tests, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)- Size, Share, Outlook, and Opportunity Analysis, 2022 – 2030

The global Lupus Therapeutic Market is estimated to be valued at US$ 2,795.2 million in 2022 and is expected to exhibit a CAGR of 8.6 % over the forecast period as highlighted in a new report published by Coherent Market Insights.

Market Overview

Lupus is an enduring disease in which the body’s resistivity system stops to know its cells and matters as self and starts bellicose them. The four main forms of lupus consist SLE, CLE, MPLE, and NL. SLE is the very usual type of lupus that leads destruction to various organs of the body such as the renal, pneumonic, cardiac, and others. SLE leads to irritation in the dermis, bones, lungs, blood tissues, renal, and others. This condition generally goes from cycles of flare-ups and reductions.

Competitive Landscape:

Key players involved in the growth of global lupus therapeutic market are Sanofi, Aurinia Pharmaceuticals Inc., Bristol-Myers Squibb Company, Hikma Pharmaceuticals PLC, Boehringer Ingelheim International Gmbh, Lupus Therapeutics, Teva Pharmaceutical Industries Ltd., Pfizer Inc., Takeda Pharmaceutical Company Limited, ImmuPharma PLC, Bayer AG,F.Hoffmann-La Roche Ltd, UCB S.A., Dr. Reddy's Laboratories Ltd., GlaxoSmithKline plc, AstraZeneca, ADMA Biologics, Inc., Amgen Inc., Merck & Co., Inc., and Novartis AG.

Market Key Drivers:

Rising research and development activities for the development in new therapies for lupus is expected to augment the growth of global lupus therapeutic market. For instance, in November 2021, AstraZeneca, a U.K. developed biopharma industry announced results from its TULIP Phase III clinical test.

Increasing focus of key players in the expansion of the product is projected to propel the growth of the global lupus therapeutic market. For instance, in December 2020, GlaxoSmithKline plc, a U.K. developed pharma company was approved by U.S. FDA for its medicine BENLYSTA to be used in combination with standard therapy for cure of geriatric people with active LN.

Covid-19 Impact Analysis:

The Covid-19 outbreak has adversely affected the growth of the global lupus therapeutic market as there was interruption in supply chain, lack of delay in other treatments, interruption in healthcare sector, and restriction on transportation of goods. However, the market was on growth as the Covid-19 treatment was related to people suffering from lupus.

Key Takeaways:

The global lupus therapeutic market is expected to exhibit a CAGR of 8.6 % during the forecast period owing to the rising collaborations and partnerships. For instance, in November 2020, iSD Immunotech, a DBC collaborated with Biogen, a U.S. origin biotech industry for advancement of a patient to be used in the therapy of ADL.

Among regions, North America, Asia Pacific and Europe anticipated to witness robust growth in the global lupus therapeutic market due to increasing cases of lupus, rising collaborations and partnerships, rising approvals and launches of products. For instance, as per WHO, around 1.5 million Americans suffer from a kind of lupus annually in U.S.